PRESS RELEASE

新闻稿

CHARM Therapeutics appoints Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development

CHARM Therapeutics任命Nicholas Edmunds博士为首席开发官，临床前开发负责人

LONDON – 30 April 2024 -- CHARM Therapeutics (“CHARM”, “The Company”), a protein-ligand intelligence company turning prediction into impactful medicines, today announces the appointment of Dr Nicholas Edmunds as Chief Development Officer, Head of Pre-Clinical Development.

伦敦——2024年4月30日——CHARM Therapeutics（“CHARM”，“The Company”）是一家蛋白质配体智能公司，将预测转化为有影响力的药物，今天宣布任命Nicholas Edmunds博士为首席开发官兼临床前开发负责人。

In this role, he will be responsible for advancing CHARM’s proprietary oncology programs towards the clinic and building out a broader translational pharmacology and preclinical development capability.

在这个职位上，他将负责推动CHARM的专有肿瘤学项目走向临床，并建立更广泛的转化药理学和临床前开发能力。

Dr Edmunds has more than two decades of experience in preclinical development, translational research, and drug discovery. He joins CHARM Therapeutics after holding several senior positions, including his most recent role as Chief Technology Officer at Mission Therapeutics, a company focused on developing novel DUB inhibitors for serious diseases including Parkinson’s Disease and Alzheimer’s Disease.

Edmunds博士在临床前开发，转化研究和药物发现方面拥有20多年的经验。在担任多个高级职位后，他加入了CHARM Therapeutics，其中包括他最近在Mission Therapeutics担任首席技术官的职位，Mission Therapeutics是一家专注于开发新型DUB抑制剂治疗帕金森病和阿尔茨海默氏病等严重疾病的公司。

In this position, he contributed to the development of the company’s proprietary drug discovery platform..

在这个职位上，他为公司专有药物发现平台的开发做出了贡献。。

Prior to joining Mission Therapeutics, Dr Edmunds worked as the Head of New Modalities, Drug Safety and Metabolism at AstraZeneca. He also spent 12 years at Pfizer working within Discovery and Preclinical Development functions in both the UK and the US. Dr Edmunds also holds a BSc in Pharmacology from the University of Leeds and a PhD from the University of Bath..

在加入Mission Therapeutics之前，Edmunds博士曾担任阿斯利康新模式，药物安全和代谢主管。他还在辉瑞公司工作了12年，在英国和美国从事发现和临床前开发职能。埃德蒙兹博士还拥有利兹大学药理学学士学位和巴斯大学博士学位。。

Laksh Aithani, Co-Founder, Chief Executive Officer and Board Member of CHARM Therapeutics, said: “On behalf of the entire team, I would like to warmly welcome Nick. DragonFold, our unique protein-ligand intelligence platform, optimizes protein-ligand binding interactions and offers category-leading accuracy in co-folding prediction.

CHARM Therapeutics联合创始人、首席执行官兼董事会成员Laksh Aithani表示：“我代表整个团队热烈欢迎Nick。DragonFold是我们独特的蛋白质-配体智能平台，它优化了蛋白质-配体结合相互作用，并在共折叠预测中提供了类别领先的准确性。

We want to leverage DragonFold to discover innovative new treatments in oncology; Nick’s expertise in drug discovery and translational development will be of immense value as we continue to evolve our platform and further develop our proprietary pipeline.”.

我们希望利用DragonFold发现肿瘤学的创新新疗法；随着我们继续发展我们的平台并进一步开发我们的专有渠道，尼克在药物发现和转化开发方面的专业知识将具有巨大的价值。”。

Dr Nicholas Edmunds, Chief Development Officer, Head of Pre-Clinical Development at CHARM Therapeutics, said: “CHARM is tackling the hardest challenges in the optimization of protein-ligand interactions in order to create powerful new medicines. With a unique blend of deep learning computing, small molecule chemistry, structural sciences and cancer biology expertise, CHARM is at the forefront of creating the game-changing medicines of the future.

CHARM Therapeutics首席开发官兼临床前开发负责人尼古拉斯·埃德蒙兹博士表示：“CHARM正在解决优化蛋白质-配体相互作用方面的最严峻挑战，以创造强大的新药。凭借深度学习计算、小分子化学、结构科学和癌症生物学专业知识的独特融合，CHARM处于创造未来改变游戏规则药物的前沿。

I am incredibly excited to be playing a part in this transformation of the biopharma paradigm and look forward to working with the whole team.”.

我非常高兴能在生物制药范式的转变中发挥作用，并期待着与整个团队合作。”。

ENDS

结束

For further information, please contact:

欲了解更多信息，请联系：

CHARM Therapeutics

魅力疗法

Laksh Aithani, Chief Executive Officer

首席执行官Laksh Aithani

Phone +44 7933 185425

电话+44 7933 185425

laksh@charmtx.com

laksh@charmtx.com

ICR Consilium

ICR Consilium

Amber Fennell /Jessica Hodgson / Davide Salvi

Amber Fennell/Jessica Hodgson/Davide Salvi

Phone: 44 (0)20 3709 5700

电话：44（0）20 3709 5700

charm@consilium-comms.com

charm@consilium-comms.com

About CHARM Therapeutics

关于魅力疗法

CHARM Therapeutics is a protein-ligand intelligence company turning advanced protein-ligand prediction into impactful medicines.

CHARM Therapeutics是一家蛋白质配体智能公司，将先进的蛋白质配体预测转化为有影响力的药物。

CHARM’s advanced protein-ligand prediction platform, DragonFold, provides unique 3D insights into the dynamic structure of the protein-ligand binding interactions, with the potential for profound impacts on the design of novel molecules and delivery of new medicines.

CHARM的高级蛋白质-配体预测平台DragonFold为蛋白质-配体结合相互作用的动态结构提供了独特的3D见解，可能对新分子的设计和新药的递送产生深远影响。

The Company’s initial focus is novel small molecules to treat cancer, but the technology is potentially applicable to many other therapeutic areas.

该公司最初的重点是治疗癌症的新型小分子，但该技术可能适用于许多其他治疗领域。

Cambridge and London-based CHARM has raised $70 million to date and is building an interdisciplinary and entrepreneurial team, combining leaders from the fields of AI and biotechnology. It is supported by high quality international investors including OrbiMed, F-Prime Capital, General Catalyst, Khosla Ventures, Bristol Myers Squibb, NVIDIA and Grep VC For more information, please visit: www.charmtx.com.

剑桥和伦敦的CHARM迄今已筹集了7000万美元，并正在建立一个跨学科和创业团队，由人工智能和生物技术领域的领导者组成。它得到了包括OrbiMed、F-Prime Capital、General Catalyst、Khosla Ventures、Bristol-Myers Squibb、NVIDIA和Grep VC在内的优质国际投资者的支持。有关更多信息，请访问：www.charmtx.com。